FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Sarepta Therapeutics, Inc. - Common Stock
(NQ:
SRPT
)
17.50
UNCHANGED
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sarepta Therapeutics, Inc. - Common Stock
< Previous
1
2
...
30
31
32
33
34
35
36
37
Next >
2 Under-the-Radar Biotech Stocks to Buy in 2023
↗
January 06, 2023
These biotechnology stocks are pushing ahead with promising innovations.
Via
The Motley Fool
Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
January 05, 2023
From
Catalent, Inc.
Via
Business Wire
BTIG Maintains Buy Rating for Sarepta Therapeutics: Here's What You Need To Know
↗
December 22, 2022
Via
Benzinga
2 Top Healthcare Stocks to Buy for the Long Haul
↗
December 09, 2022
These two companies are just getting started.
Via
The Motley Fool
Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review
↗
December 02, 2022
The S&P 500 is fighting for its 200-day, a critical level for the uptrend.
Via
Investor's Business Daily
Analyst Ratings for Sarepta Therapeutics
↗
November 03, 2022
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:
Via
Benzinga
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy
↗
November 28, 2022
Sarepta Therapeutic is nearing the finish line with its Duchenne muscular dystrophy gene therapy.
Via
Investor's Business Daily
Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript
↗
November 03, 2022
SRPT earnings call for the period ending September 30, 2022.
Via
The Motley Fool
3 Unstoppable Stocks That Could Double in 5 Years
↗
October 29, 2022
The opportunities for these innovators are tremendous.
Via
The Motley Fool
2 Under-the-Radar Biotech Stocks to Buy in 2022
↗
October 19, 2022
These two drugmakers are growing in prominence.
Via
The Motley Fool
Apple To $177? Plus This Analyst Slashes PT On Opendoor Technologies By About 71%
↗
October 17, 2022
Morgan Stanley cut Apple Inc. (NASDAQ: AAPL) price target from $180 to $177. Apple shares rose 1.1% to $139.95 in pre-market trading.
Via
Benzinga
Is Pfizer Stock Still Worth Buying After the Pandemic?
October 12, 2022
Pharmaceutical giant Pfizer (NYSE: PFE) is literally synonymous with COVID-19 vaccines, and as a result, Pfizer stock continues to beat expectations.
Via
MarketBeat
Analyst Ratings for Sarepta Therapeutics
↗
September 08, 2022
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:
Via
Benzinga
FDA Lifts Clinical Hold On Sarepta's Dose-Expansion Part Of Duchenne Trial
↗
September 06, 2022
Via
Benzinga
Earnings Scheduled For November 2, 2022
↗
November 02, 2022
Companies Reporting Before The Bell • Nomura Holdings (NYSE:NMR) is likely to report earnings for its second quarter.
Via
Benzinga
7 Analysts Have This to Say About Sarepta Therapeutics
↗
October 13, 2022
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter:
Via
Benzinga
Sarepta In-Licenses Next-Gen AAV Tech Covering Five Indications
↗
August 08, 2022
Via
Benzinga
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
September 29, 2022
Via
AB Newswire
A Trio of Q3 Winners With Room to Run
September 29, 2022
It's those rare bright spots in a dim market that can be the best places to hide. Here are three Q3 outperformers that still have good upside.
Via
MarketBeat
Topics
Economy
Stocks
PepGen's Duchenne Candidate Has Potential For Greater Exon Skipping Capabilities At Lower Doses Versus Sarepta's Candidate, Says Analyst
↗
September 28, 2022
Via
Benzinga
$6 Million Bet On Sarepta Therapeutics? 3 Stocks Insiders Are Buying
↗
September 16, 2022
Although US stocks closed lower on Thursday, there were a few notable insider trades.
Via
Benzinga
Sarepta's Duchenne Gene Therapy Update Gets Bullish Stance From Analysts
↗
August 03, 2022
Via
Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
↗
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
A Biotech's Stock Just Hit Year High. This Analyst Expects It To Jump Another 16%
↗
September 08, 2022
Morgan Stanley raised the price target on Sarepta Therapeutics Inc (NASDAQ: SRPT) with an equal weight rating.
Via
Benzinga
15 Biotech Stocks That Hit Year Highs Over The Last Week, Including Sarepta, Axsome
↗
August 30, 2022
Not all shares are slowing down alongside the industry group.
Via
Investor's Business Daily
Is Biotech Back? This Analyst Sees 18% Upside Potential In This Bio Play
↗
August 08, 2022
Sarepta Therapeutics Inc. (NASDAQ: SRPT), a pioneer in precision genetic medicine for rare diseases, announced Monday that it had signed licensing agreements with the Broad Institutes of both MIT and...
Via
Benzinga
Sarepta Therapeutics: Q2 Earnings Insights
↗
August 02, 2022
Sarepta Therapeutics (NASDAQ:SRPT) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings Sarepta Therapeutics...
Via
Benzinga
Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
↗
August 02, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Sarepta Therapeutics Earnings Preview
↗
August 01, 2022
Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-08-02. Here's what investors need to know before the announcement. Analysts estimate that Sarepta...
Via
Benzinga
Earnings Scheduled For August 2, 2022
↗
August 02, 2022
Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.
Via
Benzinga
< Previous
1
2
...
30
31
32
33
34
35
36
37
Next >
